ADHERENCE AND PERSISTENCE OF PCSK9 INHIBITORS IN CLINICAL PRACTICE: THE REAL-WORLD ITALIAN EXPERIENCE (AT-TARGET-IT STUDY)

被引：0
|
作者：
Marzano, Federica [1 ]
Basile, Christian [2 ]
Paolillo, Stefania [2 ]
Cesaro, Arturo [3 ]
Buonocore, Davide [2 ]
Asile, Gaetano [2 ]
Abbate, Vincenza [2 ]
Vicidomini, Francesca [2 ]
Spaccarotella, Carmen Anna Maria [2 ]
Spirito, Giulio [4 ]
Maloberti, Alessandro [5 ,6 ]
Iannuzzo, Gabriella [7 ]
Ciccone, Marco Matteo [8 ]
D'alleva, Alberto [9 ]
Corleto, Antonella [10 ]
Brunetti, Natale Daniele [11 ]
Indolfi, Ciro [12 ]
Gargiulo, Paola [2 ]
Perrone-filardi, Pasquale [2 ]
机构：
[1] IRCCS Synlab Sdn, Naples, Italy
[2] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Caserta, CE, Italy
[4] Eboli Battipaglia Roccadaspide Maria Ss Addolorat, Emergency Dept, Div Cardiol, Eboli, Italy
[5] Asst Gom Niguarda, Div Cardiol 4, Cardioctr De Gasperi, Milan, Italy
[6] Bicocca Univ, Milan, Italy
[7] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[8] Univ Bari, Sch Cardiol, Bari, Italy
[9] Santo Spirito Hosp, Ccu Intervent Cardiol, Pescara, Italy
[10] Asl Torino 3, Rivoli Infermi Hosp, Turin, Italy
[11] Policlin Riuniti Univ Hosp, Cardiothorac Dept, Foggia, Italy
[12] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2022年 / 24卷
关键词：
D O I：
10.1093/eurheartjsupp/suac121.706
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
555
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT)
    Gargiulo, Paola
    Basile, Christian
    Cesaro, Arturo
    Marzano, Federica
    Buonocore, Davide
    Asile, Gaetano
    Abbate, Vincenza
    Vicidomini, Francesca
    Paolillo, Stefania
    Spaccarotella, Carmen Anna Maria
    Catalano, Angelo
    Spirito, Giulio
    Merlini, Piera Angelica
    Maloberti, Alessandro
    Iannuzzo, Gabriella
    Ciccone, Marco Matteo
    Zito, Anna Paola
    Paloscia, Leonardo
    D'Alleva, Alberto
    Varbella, Ferdinando
    Corleto, Antonella
    Brunetti, Natale Daniele
    Corbo, Maria Delia
    Calabro, Paolo
    Indolfi, Ciro
    Perrone-Filardi, Pasquale
    ATHEROSCLEROSIS, 2023, 366 : 32 - 39
  • [2] Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)
    Gargiulo, P.
    Basile, C.
    Calabro', P.
    Catalano, A.
    Merlini, P. A.
    Iannuzzo, G.
    Ciccone, M. M.
    Paloscia, L.
    Varbella, F.
    Brunetti, N. D.
    Paolillo, S.
    Marzano, F.
    Indolfi, C.
    Perrone-Filardi, P.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [3] Safety, adherence and efficacy of PCSK9 inhibitors: a retrospective real-world study
    Chng, Bee Ling Kelly
    Heng, Wei Min Paul
    Soon, Yu Ming
    Hon, Jin Shing
    Lau, Yee How
    Tan, Ru San
    Tan, Jack Wei Chieh
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2022, 31
  • [4] Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
    Gurgoze, Muhammed T.
    Muller-Hansma, Annemarie H. G.
    Schreuder, Michelle M.
    Galema-Boers, Annette M. H.
    Boersma, Eric
    van Lennep, Jeanine E. Roeters
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (02) : 496 - 504
  • [5] PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
    Perrone-Filardi, P.
    Basile, C.
    Asile, G.
    Abbate, C.
    Catalano, A.
    Merlini, P. A.
    Calabro', P.
    Iannuzzo, G.
    Ciccone, M. M.
    Paloscia, L.
    Varbella, F.
    Brunetti, N. D.
    Indolfi, C.
    Paolillo, S.
    Gargiulo, P.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2378 - 2378
  • [6] Real-world use of PCSK9 inhibitors: A single-center experience
    Sarsam, Sinan
    Berry, Abeer
    Degheim, George
    Singh, Robby
    Zughaib, Marcel
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (01) : 265 - 270
  • [7] Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings
    Muntner, Paul
    Ghazi, Lama
    Jones, Jenna
    Dhalwani, Nafeesa
    Poudel, Bharat
    Wen, Ying
    Chen, Ligong
    Wang, Zhixin
    Bittner, Vera
    Kalich, Bethany
    Farkouh, Michael E.
    Woodward, Mark
    Colantonio, Lisandro D.
    Rosenson, Robert S.
    ADVANCES IN THERAPY, 2024, 41 (06) : 2399 - 2413
  • [8] Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
    Blanco-Ruiz, Marina
    Amaya-Pascasio, Laura
    de Torres Chacon, Reyes
    Josefa Alvarez Soria, Maria
    Arjona-Padillo, Antonio
    Carrillo Bailen, Maria Magdalena
    Milan Pinilla, Rodrigo
    Perez Ortega, Irene
    Sanchez Rodriguez, Belen
    Andrade Zumarraga, Luis
    Valverde Moyano, Roberto
    Payan Ortiz, Manuel
    Castillo Fernandez, Alba Maria
    Del Toro Perez, Cristina
    Gonzalez Bustos, Pablo
    Aguera Morales, Eduardo
    Sanchez Lopez, Purificacion
    Hidalgo Martin, Beatriz
    Roa Chamorro, Ricardo
    Fernandez Perez, Javier
    Mejias Olmedo, Maria Victoria
    Martinez-Sanchez, Patricia
    ATHEROSCLEROSIS PLUS, 2021, 45 : 32 - 38
  • [9] Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study
    Deng, Zhifang
    Liu, Jue
    Gong, Hongjian
    Cai, Xiaonan
    Xiao, Han
    Gao, Wenqi
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (04)
  • [10] Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
    Goldman, Adam
    Raschi, Emanuel
    Cukierman-Yaffe, Tali
    Dankner, Rachel
    Shouval, Roni
    Shechter, Michael
    Ben-Zvi, Ilan
    Gerstein, Hertzel C.
    Maor, Elad
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (09) : 1334 - 1342
12345